| Features: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Berbamine — berbamine is a natural bisbenzylisoquinoline alkaloid with pleiotropic anticancer signaling activity. It is best classified as a plant-derived small-molecule natural product and investigational anticancer lead rather than an approved oncology drug. Standard abbreviation: BBM. It is chiefly isolated from Berberis species, especially Berberis amurensis, and has also been reported in other alkaloid-containing medicinal plants. The strongest mechanistic signal in cancer appears to be inhibition of CaMKIIγ-centered survival signaling, with downstream effects on c-Myc, STAT3, β-catenin, PI3K/Akt-related survival programs, apoptosis, and in some models ROS-linked stress responses. Clinical oncology translation remains limited; most evidence is preclinical, and formulation constraints have been noted because native berbamine has limited tumor-site exposure and short plasma persistence in vivo. Primary mechanisms (ranked):
Bioavailability / PK relevance: Native berbamine appears PK-limited for systemic oncology use. Multiple papers describe short plasma half-life or poor tumor-site exposure as a practical limitation, which is one reason nanoparticle and derivative strategies have been pursued. I did not find a robust modern human PK package for parent berbamine suitable for quantitative clinical extrapolation; stronger PK data were easier to find for derivatives than for the native compound. In-vitro vs systemic exposure relevance: Many mechanistic cancer studies use micromolar in-vitro concentrations, often around 5–20 μM and sometimes higher. That makes direct translation to achievable free systemic exposure uncertain for native berbamine. Mechanistic direction is plausible, but potency-to-exposure matching remains a major translational bottleneck unless formulation or structural optimization is used. Clinical evidence status: Preclinical for cancer. Evidence includes cell culture and xenograft studies across leukemia and several solid tumors, plus medicinal-chemistry optimization work on derivatives. I did not find established randomized oncology trials or standard clinical deployment for cancer treatment. Berbamine is a bisbenzylisoquinoline alkaloid, meaning it is composed of two benzylisoquinoline moieties. Its unique structure distinguishes it from many other natural alkaloids Berbamine is most often isolated from the plant Berberis, commonly known as barberry. Various species within this genus have been used in traditional Chinese medicine and other herbal traditions. plants in genera like Stephania have also been reported to contain bisbenzylisoquinoline alkaloids like berbamine. These plants are used in various parts of Asia both for their stimulant effects and other medicinal purposes.Oxidative Stress: Berbamine can increase the production of reactive oxygen species within cancer cells. Elevated ROS levels may push cancer cells beyond their threshold of tolerance, leading to oxidative stress–induced cell death. This property also ties in with its ability to modulate apoptosis and autophagy. Berbamine is a promising natural compound with multifaceted anticancer properties. Its ability to induce apoptosis, cause cell cycle arrest, modulate key signal transduction pathways (such as JAK/STAT, NF-κB, and PI3K/Akt/mTOR), and affect autophagy, makes it a candidate for further investigation in various cancer models. A calcium channel blocker. Mechanistic relevance in cancer
P: 0–30 min |
| Source: TCGA |
| Type: Proapototic |
| TP53 is the most commonly mutated gene in human cancer. TP53 is a gene that encodes for the p53 tumor suppressor protein ; TP73 (Chr.1p36.33) and TP63 (Chr.3q28) genes that encode transcription factors p73 and p63, respectively, are TP53 homologous structures. p53 is a crucial tumor suppressor protein that plays a significant role in regulating the cell cycle, maintaining genomic stability, and preventing tumor formation. It is often referred to as the "guardian of the genome" due to its role in protecting cells from DNA damage and stress. TP53 gene, which encodes the p53 protein, is one of the most frequently mutated genes in human cancers. Overexpression of MDM2, an inhibitor of p53, can lead to decreased p53 activity even in the presence of wild-type p53. In some cancers, particularly those with mutant p53, there may be an overexpression of the p53 protein. Cancers with overexpression: Breast, lung, colorectal, overian, head and neck, Esophageal, bladder, pancreatic, and liver. |
| 5549- | BBM, | Synergistic Anticancer Effect of a Combination of Berbamine and Arcyriaflavin A against Glioblastoma Stem-like Cells |
| - | in-vitro, | GBM, | NA |
| 5539- | BBM, | Berbamine suppresses cell viability and induces apoptosis in colorectal cancer via activating p53-dependent apoptotic signaling pathway |
| - | vitro+vivo, | CRC, | SW480 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:40 Target#:236 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid